VYGR Strangle Strategy
VYGR (Voyager Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products.
VYGR (Voyager Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $193.3M, a beta of 1.31 versus the broader market, a 52-week range of 2.94-5.55, average daily share volume of 605K, a public-listing history dating back to 2015, approximately 141 full-time employees. These structural characteristics shape how VYGR stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.31 indicates VYGR has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a strangle on VYGR?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
VYGR snapshot
As of August 14, 2026, spot at $3.26, ATM IV 192.00%, IV rank 38.58%, expected move 55.04%. The strangle on VYGR below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.
Why this strangle structure on VYGR specifically: VYGR IV at 192.00% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 55.04% (roughly $1.79 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated VYGR expiries trade a higher absolute premium for lower per-day decay. Position sizing on VYGR should anchor to the underlying notional of $3.26 per share and to the trader's directional view on VYGR stock.
VYGR strangle setup
The VYGR strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With VYGR at $3.26 on that close, the first option leg uses a $3.42 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed VYGR chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 VYGR shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $3.42 | N/A |
| Buy 1 | Put | $3.10 | N/A |
VYGR strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
VYGR strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on VYGR. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on VYGR
Strangles on VYGR are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the VYGR chain.
VYGR thesis for this strangle
The market-implied 1-standard-deviation range for VYGR extends from approximately $1.47 on the downside to $5.05 on the upside. A VYGR long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current VYGR IV rank near 38.58% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on VYGR should anchor more to the directional view and the expected-move geometry. As a Healthcare name, VYGR options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to VYGR-specific events.
VYGR strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. VYGR positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move VYGR alongside the broader basket even when VYGR-specific fundamentals are unchanged. Always rebuild the position from current VYGR chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on VYGR?
- A strangle on VYGR is the strangle strategy applied to VYGR (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With VYGR stock at $3.26 on the most recent close, the strikes shown on this page are snapped to the nearest listed VYGR chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are VYGR strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the VYGR strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 192.00%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a VYGR strangle?
- The breakeven for the VYGR strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The VYGR market-implied 1-standard-deviation expected move in the same options snapshot is approximately 55.04%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on VYGR?
- Strangles on VYGR are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the VYGR chain.
- How does current VYGR implied volatility affect this strangle?
- VYGR ATM IV is at 192.00% with IV rank near 38.58%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.